as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹118.22
Change
-5.64 (-4.55%)
Open
₹124.0
Prev. Close
₹123.86
Day High
₹124.0
Day Low
₹111.0
Volume Analysis
Traded
11,075
Delivered
8,258
Delivery %
74.56%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹137.48 | ₹130.74 | ₹124.48 | ₹117.74 | ₹111.48 | ₹104.74 | ₹98.48 |
| Fibonacci | ₹130.74 | ₹125.77 | ₹122.71 | ₹117.74 | ₹112.77 | ₹109.71 | ₹104.74 |
| Camarilla | ₹121.8 | ₹120.6 | ₹119.41 | ₹117.74 | ₹117.03 | ₹115.84 | ₹114.65 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-0.17%
1 Month
-7.93%
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹138.25
Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
9.34%
Net margin 3.57% × asset turnover 1.09x × equity multiplier 2.4x
Company Overview
Sector
Healthcare
Market Cap
₹149 Cr
P/E (TTM)
14.8
ROE
14.4%
Book Value
₹82.8
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Parnax Lab Ltd. lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 55/100. The strongest factor is Growth (75/100), while Cash Flow (27/100) is the weakest area to weigh before deciding.
TopFund Score — Fundamentals Quality
55/100 — AverageData confidence: 73/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Business Quality
Liquidity
From Screener.in
- +Company is expected to give good quarter
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company might be capitalizing the interest cost
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
The Newspaper Advertisement regarding AGM Notice for the year ended March 31, 2026.
Parnax Lab issued 44th Annual Report; AGM on 29 September 2026 with auditor and related-party approvals.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 49 | 43 | 51 | 46 | 50 | 48 | 40 | 49 | 53 | 63 | 63 | 70 | 57 |
| Expenses + | 42 | 37 | 45 | 41 | 42 | 41 | 36 | 42 | 46 | 55 | 56 | 65 | 52 |
| Operating Profit | 7 | 5 | 6 | 6 | 9 | 7 | 4 | 7 | 7 | 8 | 7 | 5 | 4 |
| OPM % | 13.34% | 12.41% | 11.71% | 12.49% | 17.2% | 14.97% | 10.62% | 13.52% | 13.94% | 12.91% | 10.88% | 7.01% | 7.59% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 0 |
| Interest | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 4 | 2 | 3 | 3 | 5 | 5 | 1 | 4 | 4 | 5 | 3 | 3 | 1 |
| Tax % | 16.33% | 20.09% | 25.85% | 19.35% | 26.3% | 29.77% | 16.67% | 26.08% | 26.46% | 30.33% | 16.62% | 27.09% | 28.33% |
| Net Profit + | 3 | 2 | 2 | 2 | 4 | 3 | 1 | 3 | 3 | 4 | 3 | 2 | 0 |
| EPS in Rs | 3 | 2 | 2 | 2 | 3 | 3 | 1 | 3 | 3 | 3 | 2 | 2 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 103 | 71 | 95 | 106 | 109 | 95 | 90 | 163 | 168 | 189 | 188 | 249 | 252 |
| Expenses + | 91 | 61 | 82 | 95 | 99 | 89 | 80 | 140 | 145 | 165 | 161 | 221 | 228 |
| Operating Profit | 12 | 10 | 13 | 10 | 10 | 6 | 10 | 23 | 23 | 24 | 27 | 27 | 24 |
| OPM % | 12.0% | 14.0% | 14.0% | 10.0% | 9.0% | 7.0% | 11.0% | 14.0% | 14.0% | 12.0% | 14.0% | 11.0% | 10.0% |
| Other Income + | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 2 |
| Interest | 4 | 4 | 5 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Depreciation | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 7 | 7 | 7 | 8 | 8 |
| Profit before tax | 5 | 3 | 5 | 3 | 5 | -2 | 0 | 12 | 12 | 12 | 16 | 16 | 12 |
| Tax % | 22.0% | 28.0% | 22.0% | 65.0% | 28.0% | 48.0% | 350.0% | 33.0% | 30.0% | 20.0% | 26.0% | 26.0% | — |
| Net Profit + | 4 | 3 | 4 | 1 | 3 | -3 | 0 | 8 | 9 | 10 | 12 | 12 | 9 |
| EPS in Rs | 5 | 3 | 4 | 1 | 4 | -3 | 0 | 8 | 8 | 8 | 10 | 10 | 8 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 17 | 19 | 23 | 24 | 27 | 24 | 24 | 38 | 51 | 60 | 72 | 84 |
| Borrowings + | 41 | 42 | 39 | 37 | 42 | 51 | 59 | 69 | 55 | 81 | 70 | 83 |
| Other Liabilities + | 17 | 10 | 15 | 18 | 17 | 23 | 15 | 36 | 28 | 38 | 37 | 50 |
| Total Liabilities | 83 | 79 | 86 | 87 | 95 | 107 | 106 | 153 | 145 | 190 | 190 | 228 |
| Fixed Assets + | 36 | 38 | 47 | 44 | 51 | 58 | 60 | 72 | 77 | 89 | 88 | 115 |
| CWIP | 1 | 2 | 0 | 0 | 0 | 3 | 5 | 3 | 2 | 21 | 29 | 11 |
| Investments | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 45 | 38 | 38 | 43 | 43 | 46 | 41 | 78 | 66 | 80 | 72 | 101 |
| Total Assets | 83 | 79 | 86 | 87 | 95 | 107 | 106 | 153 | 145 | 190 | 190 | 228 |
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 11 | 11 | 11 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 3 | 16 | 13 | 9 | 9 | 6 | 9 | 21 | 16 | 32 | 8 |
| Cash from Investing Activity + | -4 | -6 | -10 | -5 | -11 | -13 | -7 | -16 | -10 | -32 | -16 | -16 |
| Cash from Financing Activity + | 6 | 1 | -5 | -7 | 1 | 5 | 0 | 12 | -14 | 15 | -16 | 8 |
| Net Cash Flow | 1 | -2 | 0 | 1 | -1 | 0 | 0 | 4 | -3 | -1 | 0 | 0 |
| CFO/OP | 15 | 46 | 134 | 134 | 99 | 153 | 71 | 38 | 103 | 79 | 130 | 42 |
| Free Cash Flow | -4 | -3 | 5 | 8 | -3 | -4 | 0 | -8 | 11 | -16 | 16 | -9 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 27.69% | 27.7% | 27.7% | 27.7% | 27.71% | 27.71% | 27.7% | 27.7% | 27.71% | 27.7% | 27.71% | 27.71% |
| Promoters | 72.3% | 72.3% | 72.3% | 72.3% | 72.3% | 72.3% | 72.3% | 72.3% | 72.3% | 72.3% | 72.3% | 72.3% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Parnax Lab Ltd. (this stock) | 149 | 14.8 | 1.56 | 14.4% |
| Balaxi Pharma Ltd | 126 | 52.0 | 0.51 | 0.59% |
| Alpa Laboratories Ltd | 124 | 30.6 | 0.67 | 8.39% |
| Bal Pharma Ltd. | 175 | 24.4 | 2.13 | 7.87% |
| Natural Capsules Limited | 176 | — | 1.01 | -9.45% |
| Brooks Lab Limited | 180 | 13.7 | 1.47 | 22.0% |
| Vaishali Pharma Limited | 112 | 25.2 | 1.63 | 6.02% |
Which Mutual Funds Hold Parnax Lab Ltd.?
Frequently Asked Questions about Parnax Lab Ltd.
Parnax Lab Ltd. (PARNAXLAB) closed at ₹118.22 on NSE on 25 September 2026, down 5.64 (4.55%) from the previous close.
Parnax Lab Ltd. trades on the NSE (National Stock Exchange of India) under the symbol PARNAXLAB.
Parnax Lab Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 14.8.
Parnax Lab Ltd. has a dividend yield of 0.0%.
Parnax Lab Ltd.'s 52-week high is ₹182.0 and its 52-week low is ₹99.2.
Parnax Lab Ltd. has a market capitalisation of ₹149 crore.
Parnax Lab Ltd. has a TopFund Quality Score of 55/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Parnax Lab Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.